Welcome to our dedicated page for Inotiv news (Ticker: NOTV), a resource for investors and traders seeking the latest updates and insights on Inotiv stock.
Inotiv, Inc. (NASDAQ: NOTV) is a contract research organization focused on nonclinical and analytical drug discovery and development services and research models and related products and services. The NOTV news feed on Stock Titan brings together company-issued updates, earnings announcements, strategic collaborations, legal and regulatory disclosures, and operational developments that shape the outlook for this preclinical services provider.
Investors and industry observers following Inotiv’s news can track segment trends in its Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) businesses, including commentary on safety assessment, general toxicology, biotherapeutic analysis, discovery and translational sciences, and non-human primate (NHP) product and service revenues. Regular earnings releases and preliminary results updates provide insight into revenue mix, operating performance, backlog, and book-to-bill ratios across these segments.
Inotiv’s news flow also covers strategic initiatives such as its collaboration with VUGENE to integrate an AI-enabled bioinformatics and computational platform into its Discovery & Translational Sciences Division, and its initiative to leverage LifeNet Health’s TruVivo system to incorporate human-relevant in vitro models into its disease pharmacology offering. These items offer context on how the company is incorporating new approach methodologies and data-driven tools into early-stage research support.
Regulatory and legal developments are another key component of NOTV news. Filings and press releases have addressed matters such as settlements of securities class action and derivative litigation, updates on investigations related to non-human primate importations, and disclosures about a cybersecurity incident and related privacy class actions. Capital structure updates, including engagement of financial advisors to explore debt refinancing alternatives and activity on credit facilities, also appear in the company’s communications.
By reviewing the NOTV news page, readers can follow how Inotiv communicates its financial results, operational progress, collaborations, risk factors, and governance changes over time, all directly based on its public disclosures.
Inotiv (NASDAQ: NOTV) announced a significant expansion in its capacity to conduct Good Laboratory Practices (GLP) studies for in vitro cytogenetics and bacterial mutation assays. This enhancement is part of the Standard Battery of genetic toxicology studies needed for first-in-human evaluations of new therapeutics. Following the acquisition of genetic toxicology assets from MilliporeSigma in July 2021 and Integrated Laboratory Systems in January 2022, Inotiv aims to meet increasing demand and achieve full operational capacity by early 2023.
Inotiv, Inc. (NASDAQ: NOTV) announced a settlement involving Envigo and the U.S. DOJ/USDA regarding the Cumberland Facility. The court-approved settlement, dated July 15, 2022, does not impose fines and denies any admission of liability by Envigo. It includes a transfer plan for the facility's orderly closure, expected to take about 60 days. Inotiv plans to cease operations at this facility, which contributed less than 1% of total sales and has not been profitable since acquisition. This strategic decision follows prior disclosures about the need for facility improvements.
Inotiv, Inc. (NASDAQ: NOTV) has successfully acquired Protypia, Inc., a Nashville-based company specializing in protein/peptide bioanalytical services, for approximately $11 million. This acquisition, comprised of $9.5 million in cash and shares, enhances Inotiv’s capabilities in mass spectrometry and supports drug development across key areas such as immuno-oncology and gene therapy. The company aims to integrate Protypia's technology to improve clinical trial efficacy and retain all existing Protypia employees.
Inotiv, Inc. (NASDAQ: NOTV) announces the appointment of Glenn Washer as Group President, Safety Assessment, effective June 20, 2022. This new role aims to enhance the Company's safety assessment services globally. Washer, a board-certified toxicologist with over 35 years of CRO/biopharma experience, previously led initiatives at Frontage Laboratories and Charles River Laboratories. His responsibilities will focus on growing the safety assessment business, improving processes, and delivering excellent client experiences. Inotiv remains committed to advancing drug discovery and development services.
Inotiv, Inc. (NASDAQ: NOTV) announced the closure of two Envigo RMS facilities in Virginia, including a canine facility in Cumberland and a rodent breeding facility in Dublin, as part of corporate restructuring. The Cumberland facility, comprising less than 1% of total revenue, will not receive further investments due to the increased costs associated with required improvements. The Dublin closure is aimed at reducing capital expenditures and enhancing operational efficiency. These changes are not expected to impact financial guidance for fiscal year 2022.
Inotiv, Inc. (NASDAQ: NOTV), a contract research organization, has announced participation in several upcoming investor conferences. Key appearances include:
- UBS Global Healthcare Conference, May 24, 2022, at 7:45 a.m. ET in New York City.
- Craig-Hallum Institutional Investor Conference, June 1, 2022, virtually.
- Jefferies Healthcare Conference, June 10, 2022, at 12:15 p.m. ET in New York City.
Webcasts of the presentations will be available on Inotiv's website.
Inotiv, a leader in contract research services, reported Q2 FY 2022 revenue of $140.3 million, a remarkable growth of 646.3% year-over-year, attributed to strategic acquisitions and internal initiatives. Gross profit surged 609.5% to $44.7 million. However, the net loss widened to $(6.1) million, with operating expenses increasing significantly due to acquisitions and internal investments. The adjusted EBITDA jumped 1,846.2% to $25.3 million, indicating strong operational leverage. Guidance for H2 FY 2022 projects revenue of $290 million, aiming for a total of at least $510 million for the fiscal year.
Inotiv, Inc. (NASDAQ: NOTV) announced it will release its financial results for Q2 FY2022 on May 12, 2022, after market close. A conference call will follow at 4:30 p.m. ET the same day to discuss the results. Interested participants can join via specified domestic and international phone numbers. The call will also be webcasted and accessible through the company's investors' section. The company focuses on providing nonclinical and analytical drug discovery services.
On April 25, 2022, Inotiv, Inc. (NASDAQ: NOTV) announced the acquisition of Histion, LLC, as part of its strategy to expand specialized pathology services. This acquisition enhances Inotiv's histology operations in the plastics and medical device sectors, supporting its previously announced expansion of surgical models and medical device testing services in Fort Collins, CO. Chief Operating Officer Greg Beattie emphasized the benefits of Histion's expertise in improving client support, while Histion's President Peggy Lalor expressed enthusiasm about integrating their pathology services with Inotiv's offerings.
Inotiv, Inc. (NASDAQ: NOTV) reported a significant 370.4% revenue increase for Q1 FY 2022, totaling $84.2 million, compared to $17.9 million in Q1 FY 2021. This growth was driven by acquisitions and internal growth. However, the company recorded a net loss of $83.0 million, or $(3.93) per share, reflecting increased operating expenses, including $23.0 million in stock compensation due to acquisitions. Adjusted EBITDA rose to $10.1 million, up 621.4%. DSA backlog increased 130.9% to $104.6 million, indicating robust future revenue prospects.